Article Versions Notes

Lyon A, Tripathi R, Meeks C, He D, Wu Y, Liu J, Wang C, Chen J, Zhu H, Mukherjee S, et al. ABL1/2 and DDR1 Drive MEKi Resistance in NRAS-Mutant Melanomas by Stabilizing RAF/MYC/ETS1 and Promoting RAF Homodimerization. Cancers. 2023; 15(3):954. https://doi.org/10.3390/cancers15030954

Lyon, Anastasia, Rakshamani Tripathi, Christina Meeks, Daheng He, Yuanyuan Wu, Jinpeng Liu, Chi Wang, Jing Chen, Haining Zhu, Sujata Mukherjee, and et al. 2023. "ABL1/2 and DDR1 Drive MEKi Resistance in NRAS-Mutant Melanomas by Stabilizing RAF/MYC/ETS1 and Promoting RAF Homodimerization" Cancers 15, no. 3: 954. https://doi.org/10.3390/cancers15030954

Lyon, A., Tripathi, R., Meeks, C., He, D., Wu, Y., Liu, J., Wang, C., Chen, J., Zhu, H., Mukherjee, S., Ganguly, S., & Plattner, R. (2023). ABL1/2 and DDR1 Drive MEKi Resistance in NRAS-Mutant Melanomas by Stabilizing RAF/MYC/ETS1 and Promoting RAF Homodimerization. Cancers, 15(3), 954. https://doi.org/10.3390/cancers15030954